<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oramed Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc</link>
<description>Latest news and press releases for Oramed Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oramed-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a72378dffbe2df10bcf8.webp</url>
<title>Oramed Pharmaceuticals Inc</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc</link>
</image>
<item>
<title>Lifeward Successfully Closes on Strategic Partnership with Oramed</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/lifeward-successfully-closes-on-strategic-partnership-with-oramed</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/lifeward-successfully-closes-on-strategic-partnership-with-oramed</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in</description>
</item>
<item>
<title>Oramed and Lifeward Announce Strategic Transaction</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-and-lifeward-announce-strategic-transaction-2026-01-13</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-and-lifeward-announce-strategic-transaction-2026-01-13</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant ShareholderOramed will</description>
</item>
<item>
<title>Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/lifeward-enters-transformative-strategic-investment-and-partnership-agreement-oramed</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/lifeward-enters-transformative-strategic-investment-and-partnership-agreement-oramed</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment</description>
</item>
<item>
<title>Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-receives-18-million-payment-135500461</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-receives-18-million-payment-135500461</guid>
<pubDate>Wed, 07 Jan 2026 13:55:00 GMT</pubDate>
<description>Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties.</description>
</item>
<item>
<title>Oramed Reports Fiscal Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-reports-fiscal-third-quarter-2025-financial-results-2025-11-17</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-reports-fiscal-third-quarter-2025-financial-results-2025-11-17</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ --</description>
</item>
<item>
<title>ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-inc-declares-dividend-distribution-common-stock-purchase</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-inc-declares-dividend-distribution-common-stock-purchase</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted</description>
</item>
<item>
<title>Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-releases-letter-shareholders-highlighting-developments-its-oral-insulin</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-releases-letter-shareholders-highlighting-developments-its-oral-insulin</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company</description>
</item>
<item>
<title>Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/scilex-holding-company-announces-the-completion-of-the-first-tranche-of-the-oramed-pharmaceuticals-inc-warrant-repurchase</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/scilex-holding-company-announces-the-completion-of-the-first-tranche-of-the-oramed-pharmaceuticals-inc-warrant-repurchase</guid>
<pubDate>Wed, 01 Oct 2025 13:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share (“Warrants</description>
</item>
<item>
<title>Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-announces-369-million-investment-and-strategic-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-announces-369-million-investment-and-strategic-collaboration</guid>
<pubDate>Mon, 28 Apr 2025 04:00:00 GMT</pubDate>
<description>Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer</description>
</item>
<item>
<title>Oramed Pharmaceuticals Issues Letter to Shareholders</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-issues-letter-shareholders-2025-03-04</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-issues-letter-shareholders-2025-03-04</guid>
<pubDate>Tue, 04 Mar 2025 05:00:00 GMT</pubDate>
<description>Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S.</description>
</item>
<item>
<title>Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-announces-transformative-joint-venture-accelerate-development-and</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-announces-transformative-joint-venture-accelerate-development-and</guid>
<pubDate>Tue, 11 Feb 2025 05:00:00 GMT</pubDate>
<description>New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed</description>
</item>
<item>
<title>Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-announces-restructuring-scilex-holding-company-debt-2024-10-07</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-announces-restructuring-scilex-holding-company-debt-2024-10-07</guid>
<pubDate>Mon, 07 Oct 2024 04:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on</description>
</item>
<item>
<title>Oramed Letter to Shareholders</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-letter-shareholders-2024-06-26</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-letter-shareholders-2024-06-26</guid>
<pubDate>Wed, 26 Jun 2024 04:00:00 GMT</pubDate>
<description>Stock Repurchase Program Scilex Senior Secured NotePhase 3 Oral Insulin Trial in USJV with Chinese Partner, HTITNEW YORK, June 26, 2024 /PRNewswire/ -- Oramed</description>
</item>
<item>
<title>Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-inc-announces-buy-back-its-common-stock-2024-06-26</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-pharmaceuticals-inc-announces-buy-back-its-common-stock-2024-06-26</guid>
<pubDate>Wed, 26 Jun 2024 04:00:00 GMT</pubDate>
<description>NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage</description>
</item>
<item>
<title>Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company</guid>
<pubDate>Fri, 22 Sep 2023 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the</description>
</item>
<item>
<title>Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-announces-dollar101875000-short-term-senior-secured-note-transaction-with-scilex</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-announces-dollar101875000-short-term-senior-secured-note-transaction-with-scilex</guid>
<pubDate>Thu, 21 Sep 2023 04:00:00 GMT</pubDate>
<description>18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note</description>
</item>
<item>
<title>Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-signs-term-sheet-with-htit-to-create-a-joint-venture-to-advance-oral-drug</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-signs-term-sheet-with-htit-to-create-a-joint-venture-to-advance-oral-drug</guid>
<pubDate>Wed, 02 Aug 2023 04:00:00 GMT</pubDate>
<description>JV will have global marketing rights to oral drug delivery technologyHTIT to invest $60 million, Oramed to invest $10 million into JVHTIT to provide a supply</description>
</item>
<item>
<title>Oramed to Present at the 83rd American Diabetes Association Conference</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-to-present-at-the-83rd-american-diabetes-association-conference-2023-06-20</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-to-present-at-the-83rd-american-diabetes-association-conference-2023-06-20</guid>
<pubDate>Tue, 20 Jun 2023 04:00:00 GMT</pubDate>
<description>NEW YORK, June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to</description>
</item>
<item>
<title>Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-to-present-at-novel-therapies-for-type-2-diabetes-obesity-summit-2023-05-18</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-to-present-at-novel-therapies-for-type-2-diabetes-obesity-summit-2023-05-18</guid>
<pubDate>Thu, 18 May 2023 04:00:00 GMT</pubDate>
<description>NEW YORK, May 18, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer</description>
</item>
<item>
<title>Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China</title>
<link>https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-announces-that-its-chinese-partner-htit-has-successfully-completed-a-phase-3</link>
<guid isPermaLink="true">https://6ix.com/company/oramed-pharmaceuticals-inc/news/oramed-announces-that-its-chinese-partner-htit-has-successfully-completed-a-phase-3</guid>
<pubDate>Mon, 15 May 2023 04:00:00 GMT</pubDate>
<description>Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups NEW YORK, May</description>
</item>
</channel>
</rss>